Rosiglitazone and Cardiovascular Risk

被引：15
|
作者：
Kaul, Sanjay [1 ]
Diamond, George A. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA
来源：
CURRENT ATHEROSCLEROSIS REPORTS | 2008年 / 10卷 / 05期
关键词：
D O I：
10.1007/s11883-008-0062-7
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
A meta-analysis of 42 clinical trials suggested that rosiglitazone, a widely used thiazolidinedione, was associated with a 43% greater risk of myocardial infarction (P = 0.03) and a 64% greater risk of cardiovascular death (P = 0.06). However, a number of criticisms have been raised that potentially undermine the conclusions of this analysis. In this article, we point out some of these limitations, summarize the currently available evidence concerning rosiglitazone and cardiovascular risk, share implications for drug safety evaluation, and offer practical recommendations to health care providers. We conclude that the data showing the increased risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone are inconclusive.
引用
收藏
页码：398 / 404
页数：7
相关论文
共 50 条
  • [21] Rosiglitazone and cardiovascular disease revisited
    Davis, Timothy M. E.
    Prins, Johannes B.
    MEDICAL JOURNAL OF AUSTRALIA, 2010, 193 (03) : 134 - 135
  • [22] THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER THE CARDIOVASCULAR RISK-WARNINGS: WAS THERE A DIFFERENTIAL EFFECT?
    Jain, R.
    Mullins, C. D.
    Lee, H.
    Wong, W.
    VALUE IN HEALTH, 2009, 12 (07) : A413 - A413
  • [23] Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
    Singh, Sonal
    Loke, Yoon K.
    Furberg, Curt D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (10): : 1189 - 1195
  • [24] Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus
    Irons, BK
    Greene, RS
    Mazzolini, TA
    Edwards, KL
    Sleeper, RB
    PHARMACOTHERAPY, 2006, 26 (02): : 168 - 181
  • [25] Reduction of cardiovascular risk-score in metabolic syndrome during an initial therapy with rosiglitazone
    Macic-Dzankovic, Amra
    Dzankovic, Faud
    Pojskic, B.
    Asimi, Z.
    HEALTHMED, 2009, 3 (03): : 314 - 321
  • [26] The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk
    Yee, M. S.
    Pavitt, D. V.
    Dhanjil, S.
    Godsland, I. F.
    Richmond, W.
    Johnston, D. G.
    DIABETIC MEDICINE, 2010, 27 (12) : 1392 - 1400
  • [27] ROSIGLITAZONE AND CARDIOVASCULAR RISK: NISSEN AND WOLSKI 2010 UPDATED META-ANALYSIS REVISITED
    Kaul, Sanjay
    Diamond, George A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E552 - E552
  • [28] No causal effects between rosiglitazone and cardiovascular disease or risk factors: a Mendelian randomization study
    LI, X. -M.
    Wu, Z. -J.
    Xu, Z. -l.
    LI, A.
    Liu, M. -Q.
    Song, C. -G.
    Wu, K.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (11) : 5280 - 5292
  • [29] Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?
    Hertzel C Gerstein
    Salim Yusuf
    Nature Clinical Practice Endocrinology & Metabolism, 2007, 3 : 798 - 799
  • [30] Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
    Nissen, Steven E.
    Wolski, Kathy
    ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (14) : 1191 - 1201
12345